PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?

Exquisitely exploiting defects in homologous recombination process, poly(ADP-ribose) polymerase (PARP) inhibitors have recently emerged as a promising class of therapeutics in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer with germline breast cancer 1 (BRCA1) or bre...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonçalves, Anthony, Bertucci, Alexandre, Bertucci, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352970/
https://www.ncbi.nlm.nih.gov/pubmed/32471249
http://dx.doi.org/10.3390/cancers12061378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352970/
https://www.ncbi.nlm.nih.gov/pubmed/32471249
http://dx.doi.org/10.3390/cancers12061378

Ejemplares similares